Answers are grounded in this paper and cite their sources.
This Viewpoint explores how human leukocyte antigen (HLA) restrictions limit applicability of T-cell receptor (TCR) therapies in genetically diverse populations and how stakeholders and address the disparities.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: